XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue Recognition - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2021
USD ($)
Segment
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Segment
Jun. 30, 2021
USD ($)
Segment
Jan. 01, 2022
USD ($)
Disaggregation of Revenue [Line Items]            
Provisions for revenue reserves to reduce product revenues to product revenues, net   $ 70.8 $ 61.3 $ 134.5 $ 112.1  
Second Santen Agreement | Santen            
Disaggregation of Revenue [Line Items]            
Upfront payment receivable           $ 88.0
Amount receivable, upon achievement of event           $ 2.0
Contingent payments receivable upon achievement of development and regulatory milestones (up to) $ 15.5          
Contingent payments receivable upon achievement of commercial milestones (up to) $ 60.0          
Collaborative agreement, termination by counterparty, effective after written notice period | Segment 180          
Collaborative agreement expiration, period after first commercial sale of product 3 years          
Expanded Territories Excluding China and India | Second Santen Agreement | Santen            
Disaggregation of Revenue [Line Items]            
Royalty percentage (in excess of) 25.00%          
China and India | Second Santen Agreement | Santen            
Disaggregation of Revenue [Line Items]            
Royalty percentage (in excess of) 20.00%          
Europe | Santen            
Disaggregation of Revenue [Line Items]            
Collaborative agreement, repayment of upfront payment upon termination, amount $ 8.0          
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Number of distributors | Segment       3 3  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor One            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage       37.00% 37.00%  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor Two            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage       33.00% 32.00%  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor Three            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage       28.00% 30.00%